06:37 AM EDT, 03/17/2026 (MT Newswires) -- Greenwich LifeSciences ( GLSI ) said Tuesday that preliminary data from its late-stage trial of its experimental therapy, GLSI-100, to prevent breast cancer recurrences, showed a continued reduction in recurrence rates among certain patients.

The drug developer said six months of additional patient data demonstrated recurrence rate of less than 1% per year following completion of the primary immunization series, compared to an expected 4% annual recurrence rate in a similar population.

The difference corresponds to 70% to 80% reduction in recurrence rate, the company said.

The company said the data from the study aligns with trends observed in the company's phase 2b trial, where GLSI-100 reduced breast cancer recurrences by up to 80% in patients.